Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Kedem Pharmaceuticals, focused on sublingual drug delivery system, has commenced the development of Gleevec, an anti-cancer drug to treat several blood related cancers in children and adults.
Subscribe to our email newsletter
Gleevec is the registered trade name for Imatinib, a specific inhibitor of tyrosine kinase BCR-ABL. BCR-ABL is a fusion protein created by the Philadelphia Chromosome abnormality that characterizes chronic myeloid leukemia (CML).
The oral prescription dose of Gleevec is marketed by Novartis Pharmaceuticals.
According to the company, the drug has demonstrated effective action against Chronic Myeloid Leukemia in children.
The company also claims that the sublingual formulation with taste masking features makes the drug acceptable in taste for the children with chronic dosage requirements.